MedPath

RepliCel Life Sciences, Inc.

RepliCel Life Sciences, Inc. logo
🇨🇦Canada
Ownership
Public
Established
2010-01-01
Employees
1
Market Cap
-
Website
http://www.replicel.com

Long-Term Follow-up of the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis

Withdrawn
Conditions
Tendinosis
Tendinopathy
First Posted Date
2016-01-13
Last Posted Date
2016-04-07
Lead Sponsor
RepliCel Life Sciences, Inc.
Registration Number
NCT02655042
Locations
🇨🇦

Alan McGavin Sports Medicine Centre, Vancouver, British Columbia, Canada

Study of Intradermal Injections of RCS-01 in Male and Female Subjects

Phase 1
Completed
Conditions
Intrinsic Aging of Skin
Skin Wrinkling
Solar Degeneration of Skin
Interventions
Drug: Placebo
Device: Sham injection
First Posted Date
2015-03-18
Last Posted Date
2017-10-11
Lead Sponsor
RepliCel Life Sciences, Inc.
Target Recruit Count
17
Registration Number
NCT02391935
Locations
🇩🇪

IUF Leibniz-Institut für umweltmedizinische Forschung gGmbH, Düsseldorf, Germany

Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis

Phase 1
Terminated
Conditions
Tendinosis
Tendinopathy
Interventions
Drug: Placebo
First Posted Date
2015-01-01
Last Posted Date
2017-09-28
Lead Sponsor
RepliCel Life Sciences, Inc.
Target Recruit Count
8
Registration Number
NCT02330146
Locations
🇨🇦

Allan McGavin Sports Medicine Centre, Vancouver, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath